BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
2 Cha B, Yu JH, Jin YJ, Suh YJ, Lee JW. Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database. Sci Rep 2020;10:8347. [PMID: 32433488 DOI: 10.1038/s41598-020-65460-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Kim IH, Lee SY, Kim BH, Kim JW, Lee CH, Yeon JE, Kwon SY, Um SH, Byun KS. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00157. [PMID: 32251018 DOI: 10.14309/ctg.0000000000000157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Kim TH, Lee Y, Lee YS, Gim JA, Ko E, Yim SY, Jung YK, Kang S, Kim MY, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639. [PMID: 34282172 DOI: 10.1038/s41598-021-94115-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim DY, Park JY. Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed? Hepatobiliary Surg Nutr 2019;8:522-4. [PMID: 31673545 DOI: 10.21037/hbsn.2019.05.08] [Reference Citation Analysis]
7 Kang MK, Park JG. Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2021;11:854. [PMID: 34068776 DOI: 10.3390/diagnostics11050854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep 2021;11:2884. [PMID: 33536442 DOI: 10.1038/s41598-021-81959-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lee JW, Park SH. Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation. J Affect Disord 2021;278:259-63. [PMID: 32977263 DOI: 10.1016/j.jad.2020.09.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
11 Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther 2021;43:473-99. [PMID: 33526312 DOI: 10.1016/j.clinthera.2021.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gim JA, Bang SM, Lee YS, Lee Y, Yim SY, Jung YK, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS One 2021;16:e0255822. [PMID: 34358264 DOI: 10.1371/journal.pone.0255822] [Reference Citation Analysis]
13 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
14 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Shin HK, Park JH, Yu JH, Jin YJ, Suh YJ, Lee JW, Kim W; Korean Nonalcoholic Fatty Liver Study Group (KNSG). Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. Sci Rep 2021;11:18004. [PMID: 34504179 DOI: 10.1038/s41598-021-97385-2] [Reference Citation Analysis]
16 Kim S, Lee AY, Cho MH. Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease. Heliyon 2021;7:e06452. [PMID: 33817364 DOI: 10.1016/j.heliyon.2021.e06452] [Reference Citation Analysis]
17 Kim BK, Kim SU. Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B. Aliment Pharmacol Ther 2019;50:333-4. [DOI: 10.1111/apt.15364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kang MK, Baek JH, Kweon YO, Tak WY, Jang SY, Lee YR, Hur K, Kim G, Lee HW, Han MH, Choi JH, Park SY, Park JG. Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver. Diagnostics (Basel) 2021;11:1061. [PMID: 34207587 DOI: 10.3390/diagnostics11061061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu Y, Mihna D, Izem L, Morton RE. Both full length-cholesteryl ester transfer protein and exon 9-deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes. Lipids 2021. [PMID: 34866179 DOI: 10.1002/lipd.12330] [Reference Citation Analysis]
20 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochim Biophys Acta Rev Cancer. 2019;1871:117-125. [PMID: 30528647 DOI: 10.1016/j.bbcan.2018.11.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
22 Park SH, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Jeong C, Suk KT, Kim DJ. Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. Climacteric 2020;23:173-7. [DOI: 10.1080/13697137.2019.1650018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Kim MN, Lo CH, Corey KE, Liu PH, Ma W, Zhang X, Jovani M, Song M, Chan AT, Simon TG. Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. Metabolism 2020;113:154398. [PMID: 33058854 DOI: 10.1016/j.metabol.2020.154398] [Reference Citation Analysis]
24 Eun HS. Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? Clin Mol Hepatol 2020;26:236-7. [PMID: 32272819 DOI: 10.3350/cmh.2020.0040] [Reference Citation Analysis]
25 Jeong SW. Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis? Clin Mol Hepatol 2020;26:185-6. [PMID: 32192273 DOI: 10.3350/cmh.2020.0046] [Reference Citation Analysis]
26 Starosta RT, Vairo FPE, Dornelles AD, Basgalupp SP, Siebert M, Pedroso MLA, Cerski CTS, Álvares-da-Silva MR, Schwartz IVD. Liver involvement in patients with Gaucher disease types I and III. Mol Genet Metab Rep 2020;22:100564. [PMID: 32099816 DOI: 10.1016/j.ymgmr.2019.100564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Park SH, Kim DJ, Plank LD. Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators. Eur J Clin Nutr 2020;74:1401-9. [PMID: 32152511 DOI: 10.1038/s41430-020-0591-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lee HW, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. J Diabetes Complications 2021;35:107747. [PMID: 33616043 DOI: 10.1016/j.jdiacomp.2020.107747] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Park JG, Kim G, Jang SY, Lee YR, Lee E, Lee HW, Han MH, Chun JM, Han YS, Yoon JS, Kang MK, Kweon YO, Tak WY, Park SY, Hur K. Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis. Life (Basel) 2020;10:E230. [PMID: 33022942 DOI: 10.3390/life10100230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi H. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther 2020;51:801-11. [PMID: 32133676 DOI: 10.1111/apt.15673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
31 Kim MN, Lo CH, Corey KE, Luo X, Long L, Zhang X, Chan AT, Simon TG. Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. Clin Nutr 2021;41:356-64. [PMID: 34999330 DOI: 10.1016/j.clnu.2021.12.014] [Reference Citation Analysis]
32 Chang JW, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. Gut Liver 2021;15:117-27. [PMID: 32066210 DOI: 10.5009/gnl19301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
34 Nishida N. Metabolic disease as a risk of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:87-90. [PMID: 33317238 DOI: 10.3350/cmh.2020.0302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26:209-15. [PMID: 31679316 DOI: 10.3350/cmh.2019.0065] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
36 Domech CR, Travieso JCF, Guridi ZD, Fernández MIC, Del Vallín SL, Carralero AR, Batallie EF, Alvarez AMA, Dorta LF, Ferrer JI, Castaño SM, García MR, Rivero GJ, Alvarez YV. Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2021;7:55-65. [PMID: 34027116 DOI: 10.5114/ceh.2021.104387] [Reference Citation Analysis]
37 Marin-alejandre BA, Abete I, Monreal JI, Elorz M, Benito-boillos A, Herrero JI, Navarro-blasco I, Tur JA, Bandarra NM, Zulet MA, Martinez JA. Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study. Journal of Clinical Lipidology 2020;14:837-849.e2. [DOI: 10.1016/j.jacl.2020.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Chang Y, Kim JI, Lee B, Kim SG, Jung MJ, Kim YS, Jeong SW, Jang JY, Yoo JJ. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years. Clin Mol Hepatol 2020;26:318-27. [PMID: 32447878 DOI: 10.3350/cmh.2019.0019n] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
40 Kim MJ, Lee KJ. Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017. BMC Pediatr 2020;20:121. [PMID: 32171275 DOI: 10.1186/s12887-020-02022-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Fernandez-Travieso JC, Rodriguez-Perez I, Ruenes-Domech C, lIlnait-Ferrer J, Fernandez-Dorta L, Mendoza-Castano S. Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology Res 2020;13:73-80. [PMID: 32362966 DOI: 10.14740/gr1273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Chun HS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee YH, Kim YD, Kim SU. Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. J Gastroenterol Hepatol 2021;36:1703-13. [PMID: 33370454 DOI: 10.1111/jgh.15387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kang MK, Park JG, Kim MC. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Yonsei Med J 2020;61:860-7. [PMID: 32975060 DOI: 10.3349/ymj.2020.61.10.860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]